Tau Pathology plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
[Tau[/entities/[tau-protein[/entities/[tau-protein[/entities/[tau-protein[/entities/[tau-protein--TEMP--/entities)--FIX-- Pathology is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes 45 sites, approximately 3-4 fold more than normal tau. Key pathological sites:
| Site | Antibody/Epitope | Significance |
|---|---|---|
| Ser202/Thr205 | AT8 | Most commonly used diagnostic marker; early phosphorylation event |
| Thr181 | AT270 | CSF p-tau181 biomarker |
| Thr217 | — | [p-tau217[/entities/[p-tau217[/entities/[p-tau217[/entities/[p-tau217[/entities/[p-tau217--TEMP--/entities)--FIX-- — most accurate blood-based AD biomarker |
| Thr231 | AT180 | p-tau231 — earliest CSF change; reflects [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX---driven tau phosphorylation |
| Ser396/Ser404 | PHF-1 | [Late[/diseases/[late[/diseases/[late[/diseases/[late[/diseases/[late--TEMP--/diseases)--FIX---stage phosphorylation; correlates with tangle maturity |
| Ser262 | 12E8 | Within KXGS motif in repeat domain; directly reduces MT binding |
Major tau kinases (hyperphosphorylation drivers):
Major tau phosphatases (dephosphorylation):
Kinases implicated in tau phosphorylation:
Phosphatases:
style TAU fill:#e3f2fd,stroke:#1565c0
style PHOS fill:#fff3e0,stroke:#e65100
style OLIGO fill:#fce4ec,stroke:#c62828
style PHF fill:#f3e5f5,stroke:#6a1b9a
style NFT fill:#f3e5f5,stroke:#6a1b9a
style GHOST fill:#efebe9,stroke:#4e342e
style SPREAD fill:#fff3e0,stroke:#e65100
**Tau oligomers** are now considered the most neurotoxic species, preceding fibril formation and correlating with [synaptic dysfunction[/mechanisms/[synaptic-dysfunction[/mechanisms/[synaptic-dysfunction[/mechanisms/[synaptic-dysfunction[/mechanisms/[synaptic-dysfunction--TEMP--/mechanisms)--FIX--, mitochondrial damage, and membrane disruption.
### Cryo-EM Structures of Tau Filaments
A transformative advance: cryo-EM has revealed that each tauopathy has a unique tau filament fold ([Fitzpatrick et al., 2017](https://doi.org/10.1038/nature23002)):
| Disease | Filament Type | Tau Isoforms | Core Residues | Key Structural Feature |
|---------|--------------|-------------|---------------|----------------------|
| **AD** | PHF and SF | 3R+4R | R3-R4 (306-378) | C-shaped fold; β-helix |
| **Pick's disease** | Pick body filaments | 3R | R1, R3-R4 | Elongated J-shape |
| **CBD** | CBD filaments | 4R | R1-R4 (274-380) | Four-layered; distinctive β-arch |
| **PSP** | PSP filaments | 4R | R1-R4 (272-381) | Distinct from CBD despite 4R overlap |
| **CTE** | CTE filaments | 3R+4R | R3-R4 | Unique hydrophobic cavity |
| **AGD** | AGD filaments | 4R | Similar to PSP | Closely related to PSP fold |
| **GGT** | GGT filaments | 4R | R2-R4 | Distinct glial tauopathy |
These structures demonstrate that the same tau protein]/proteins/tau adopts disease-specific conformations, supporting the concept of prion-like conformational strains <sup><a href="#references">[3]</a></sup>.
## Braak Staging
Tau pathology follows a stereotypical progression through defined brain regions ([Braak & Braak, 1991](https://doi.org/10.1007/BF00308809)):
| Braak Stage | Regions Affected | Clinical Correlation | Tau PET Pattern |
|-------------|-----------------|---------------------|-----------------|
| **I-II** (Transentorhinal) | [Entorhinal [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--, transentorhinal region | Clinically silent; pre-symptomatic | Medial temporal positivity |
| **III-IV** (Limbic) | [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX--, [amygdala[/brain-regions/[amygdala[/brain-regions/[amygdala[/brain-regions/[amygdala[/brain-regions/[amygdala--TEMP--/brain-regions)--FIX--, limbic [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX-- | Mild cognitive impairment (MCI) | Temporal and parietal spread |
| **V-VI** (Neocortical) | Association cortices → primary cortices | Moderate to severe dementia | Widespread cortical uptake |
The Braak staging pattern is now detectable in living patients using tau PET imaging (flortaucipir/18FMK-6240), enabling in vivo staging of AD 90% accuracy for AD diagnosis; approaching CSF performance
- **Plasma p-tau181**: Widely validated; distinguishes AD from non-AD dementias
- **Plasma p-tau231**: Earliest blood change, detectable at [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX--+ stage before tau PET positivity
Recent advances in ultrasensitive assays have enabled tau detection in blood:
- **Plasma p-tau181**: Highly accurate for AD diagnosis
- **Plasma [p-tau217[/entities/[p-tau217[/entities/[p-tau217[/entities/[p-tau217[/entities/[p-tau217--TEMP--/entities)--FIX--**: Superior accuracy, correlates with amyloid status
- **Plasma p-tau231**: Detects early, preclinical changes### Tau PET Imaging
- **Flortaucipir (18FAV-1451)**: FDA-approved first-generation tau PET tracer
- **18FMK-6240**: Second-generation tracer with improved specificity; cryo-EM shows 1:1 binding in PHF cleft ([Bhatt et al., 2024](https://doi.org/10.1038/s41467-024-52265-x))
- **18FPI-2620**: Detects both AD and non-AD (4R) tau
- **18FGTP1**: Used in [clinical trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials[/[clinical-trials](/clinical-trials) as outcome measure
### Biomarkers for Tau Pathology
- **[p-tau181](/biomarkers/p-tau-181)**: Phosphorylated tau at threonine 181
- **[p-tau217](/biomarkers/p-tau-217)**: Phosphorylated tau at threonine 217
- **[p-tau231](/biomarkers/p-tau-231)**: Phosphorylated tau at threonine 231
- **[Neurofilament Light Chain](/biomarkers/neurofilament-light-chain)**: Axonal damage marker
- **[14-3-3 Proteins](/biomarkers/14-3-3-proteins-csf)**: Neuronal damage markers
## Therapeutic Approaches
### Anti-Tau Immunotherapy
| Antibody | Target | Status (2025) | Key Results |
|----------|--------|---------------|-------------|
| **Semorinemab** | N-terminal tau (extracellular) | Phase 2 completed | No cognitive benefit in prodromal AD; modest effect in mild-moderate AD |
| **Bepranemab** | Mid-domain tau | Phase 2 | Slowed tau PET accumulation by ~60%; cognition data pending |
| **E2814** | MTBR tau (seed-competent) | Phase 2/3 ([DIAN]
| **JNJ-63733657** | [p-tau217[/entities/[p-tau217[/entities/[p-tau217[/entities/[p-tau217[/entities/[p-tau217--TEMP--/entities)--FIX-- | Phase 2 | Reduced CSF [p-tau217[/entities/[p-tau217[/entities/[p-tau217[/entities/[p-tau217[/entities/[p-tau217--TEMP--/entities)--FIX-- by >90% |
| **Zagotenemab** | Conformational tau | Phase 2 completed | Did not meet primary endpoints |
### Tau Antisense Oligonucleotides (ASOs)
- **BIIB080 (IONIS-MAPTRx)**: Intrathecal ASO targeting *[MAPT[/genes/[mapt[/genes/[mapt[/genes/[mapt[/genes/[mapt--TEMP--/genes)--FIX--* mRNA; reduces total tau production
- Phase 1b: ~60% reduction in CSF total tau and p-tau
- Phase 2: Tau PET slowing observed
- FDA Fast Track designation (April 2025)
- Rationale: Reducing substrate availability prevents both loss-of-function (MT destabilization) and gain-of-function (aggregation) toxicity
### Tau Aggregation Inhibitors
- **LMTM (leuco-methylthioninium)**: Methylthioninium derivative; failed Phase 3 trials as add-on therapy; monotherapy analysis suggested possible benefit
- Second-generation aggregation inhibitors in preclinical development
### Kinase Inhibitors
- **[GSK-3β[/entities/[gsk3-beta[/entities/[gsk3-beta[/entities/[gsk3-beta[/entities/[gsk3-beta--TEMP--/entities)--FIX-- inhibitors**: Tideglusib (Phase 2 in PSP — no benefit); lithium (epidemiological evidence for reduced dementia risk)
- **DYRK1A inhibitors**: Potential for Down syndrome-AD
- **[CDK5[/genes/[cdk5[/genes/[cdk5[/genes/[cdk5[/genes/[cdk5--TEMP--/genes)--FIX-- inhibitors**: Challenging due to broad [CDK5[/genes/[cdk5[/genes/[cdk5[/genes/[cdk5[/genes/[cdk5--TEMP--/genes)--FIX-- functions; p25-specific approaches in development
### Phosphatase Activators
- **[PP2A[/entities/[pp2a[/entities/[pp2a[/entities/[pp2a[/entities/[pp2a--TEMP--/entities)--FIX-- activators**: Sodium selenate (Phase 2 in PSP — increased [PP2A[/entities/[pp2a[/entities/[pp2a[/entities/[pp2a[/entities/[pp2a--TEMP--/entities)--FIX-- activity; mixed cognitive results)
- Restoring [PP2A[/entities/[pp2a[/entities/[pp2a[/entities/[pp2a[/entities/[pp2a--TEMP--/entities)--FIX-- activity to reduce tau hyperphosphorylation
## External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/) — Biomedical literature database
- [Alzforum Therapeutics Database](https://www.alzforum.org/therapeutics) — Clinical trial tracker
- [Allen Brain Atlas](https://brain-map.org/) — Brain gene expression data
## Background
The study of Tau Pathology has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying [mechanisms of neurodegeneration[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms](/mechanisms) and continues to drive therapeutic development <sup><a href="#references">[5]</a></sup>.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions <sup><a href="#references">[6]</a></sup>.
## See Also
- [Brain Regions Index[/[brain-regions[/[brain-regions[/[brain-regions[/[brain-regions[/[brain-regions[/[brain-regions[/[brain-regions[/[brain-regions](/brain-regions)
- [Proteins Index[/[proteins[/[proteins[/[proteins[/[proteins[/[proteins[/[proteins[/[proteins[/[proteins](/proteins)
- [Immunotherapy for Neurodegenerative Diseases[/treatments/[immunotherapy[/treatments/[immunotherapy[/treatments/[immunotherapy[/treatments/[immunotherapy--TEMP--/treatments)--FIX--
- [Lecanemab (Leqembi)[/treatments/[lecanemab[/treatments/[lecanemab[/treatments/[lecanemab[/treatments/[lecanemab--TEMP--/treatments)--FIX--
## Tauopathies Beyond Alzheimer's Disease
Tau pathology is not specific to [Alzheimer's Disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- but occurs in several other neurodegenerative conditions:
### Common Features
These diseases share common pathogenetic mechanisms including:
- Abnormal tau phosphorylation and aggregation
- Selective neuronal vulnerability
- Progressive clinical decline
- Variable involvement of other protein aggregates
### CSF Biomarkers
Cerebrospinal fluid biomarkers provide information about tau pathology:
- **Total tau (t-tau**: Elevated in AD, reflects neuronal damage
- **Phosphorylated tau (p-tau**: More specific for AD, correlates with tangle burden <sup><a href="#references">[20]</a></sup>
- p-tau181: Most widely used, correlates with tau PET
- [p-tau217[/entities/[p-tau217[/entities/[p-tau217[/entities/[p-tau217[/entities/[p-tau217--TEMP--/entities)--FIX--: Higher specificity, detects early changes
- p-tau235: Emerging biomarker
### Research Priorities
1. **Understanding tau strains**: Characterizing distinct tau conformations and their clinical significance
2. **Mechanisms of propagation**: Elucidating the cell biology of tau release and uptake
3. **Therapeutic development**: Optimizing anti-tau immunotherapies and small molecules
4. **Biomarker validation**: Standardizing blood-based tau biomarkers for clinical use
5. **Personalized approaches**: Targeting therapies based on individual tau pathology patterns
### Clinical Trial Landscape
Multiple anti-tau therapies are in various stages of clinical development, targeting:
- Tau aggregation
- Tau phosphorylation
- Tau clearance via immunotherapy
- Tau production (ASOs)
The failure of several high-profile anti-tau trials has highlighted the complexity of targeting tau but has also provided valuable insights into trial design, patient selection, and outcome measures <sup><a href="#references">[21]</a></sup>.
- --
## Imported Legacy Notes
# Tau Pathology in Neurodegenerative Disease
Tau pathology represents one of the most critical hallmarks of [Alzheimer's Disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- and several other neurodegenerative conditions collectively known as tauopathies. The tau protein, encoded by the **[MAPT[/genes/[mapt[/genes/[mapt[/genes/[mapt[/genes/[mapt--TEMP--/genes)--FIX--** ([Microtubule-Associated Protein Tau[/entities/[tau-protein[/entities/[tau-protein[/entities/[tau-protein[/entities/[tau-protein--TEMP--/entities)--FIX-- gene on chromosome 17q21.31, plays essential roles in neuronal function under normal conditions but undergoes pathological transformations that contribute to neurodegeneration.
## Brain Atlas Resources
The following resources provide additional data on tau protein and related genes:
- **Allen Human Brain Atlas**: [MAPT (tau expression data](https://human.brain-map.org/microarray/search/show?search_term=MAPT) — Search for [MAPT[/genes/[mapt[/genes/[mapt[/genes/[mapt[/genes/[mapt--TEMP--/genes)--FIX-- gene expression across brain regions
- **Allen Mouse Brain Atlas**: [Mapt expression in mouse brain](https://mouse.brain-map.org/search/index?query=Mapt) — Explore tau expression in mouse models
- **Allen Cell Type Atlas**: [Cell type-specific RNA-seq data](https://brain-map.org/atlases-and-data/rnaseq) — View tau expression across different cell types
- **BrainSpan Developmental Transcriptome**: [MAPT developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=MAPT) — Tau expression across brain development
## Recent Research (2025-2026)
Recent structural and assay developments in tau pathology] sharpen how conformational diversity, mutation-specific folding, and seeding competence are measured across [Alzheimer's Disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- and related tauopathies.
- **2025**: [Seeding biosensor cell line that reproduces the Alzheimer tau fold](https://pubmed.ncbi.nlm.nih.gov/41260337/) (*Journal of Biological Chemistry*) provides a reproducible functional readout for Alzheimer-type tau] seeding activity.<sup><a href="#references">[15]</a></sup>
- **2025**: [Distinct tau filament folds in human MAPT mutants P301L and P301T](https://pubmed.ncbi.nlm.nih.gov/40442318/) (*Nature Structural & Molecular Biology*) demonstrates structurally distinct mutant-specific fibrils, supporting precision subgrouping within tauopathies.<sup><a href="#references">[13]</a></sup>
- **2025**: Tau filaments with the Alzheimer fold in human [MAPT[/genes/[mapt[/genes/[mapt[/genes/[mapt[/genes/[mapt--TEMP--/genes)--FIX-- mutants V337M and R406W](https://pubmed.ncbi.nlm.nih.gov/40044789/) (*Nature Structural & Molecular Biology*) shows convergent Alzheimer-like fold adoption across additional pathogenic [MAPT[/genes/[mapt[/genes/[mapt[/genes/[mapt[/genes/[mapt--TEMP--/genes)--FIX-- backgrounds.<sup><a href="#references">[14]</a></sup>
## Visual Resources
### Neurofibrillary Tangle Histopathology
This histology image shows annotated neurofibrillary tangles relevant to Tau(/proteins/tau, [Alzheimer's Disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, and tauopathy progression staging.
Image attribution: [Mikael Haggstrom, *Histopathology of neurofibrillary tangles in Alzheimer's Disease - annotated* (CC0)(https://commons.wikimedia.org/wiki/File:Histopathology_of_neurofibrillary_tangles_in_Alzheimer%27s_disease_-_annotated.jpg)
## 2026 Research Advances
**Tau Biomarker-Based Diagnosis**: Nelson and Jicha<a href="#references" class="ref-link" data-ref-text="Nelson & Jicha, Tau Biomarker-Based Diagnosis of Alzheimer's Disease. Neurology (2026)">[X]</a> analyze tau biomarker-based diagnosis of Alzheimer's Disease and the relationship between tau pathology and the anti-[Amyloid-Beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- therapeutic window. This research advances precision medicine approaches for AD diagnosis and treatment selection.
<!-- ci040-visuals:tau-aggregation -->
## Visual Summary
### Pathway Flowchart
```mermaid
graph TD
TAU["tau protein<br/><small>Microtubule-associated</small>"] --> PHOS["Hyperphosphorylation<br/><small>GSK-3β, CDK5</small>"] -->
PHOS --> DETACH["MT Detachment<br/><small>Microtubule destabilization</small>"] -->
DETACH --> OLIGO["Tau Oligomers<br/><small>Soluble toxic species</small>"] -->
OLIGO --> PHF["Paired Helical Filaments<br/><small>PHFs</small>"] -->
PHF --> NFT["Neurofibrillary Tangles<br/><small>Braak staging</small>"] -->
NFT --> DEATH["Neurodegeneration<br/><small>Synaptic loss</small>"] -->
OLIGO --> SPREAD["Prion-like Spreading<br/><small>Cell-to-cell</small>"] -->
SPREAD --> DEATH
style TAU fill:#e3f2fd,stroke:#1565c0
style PHOS fill:#fff3e0,stroke:#e65100
style DETACH fill:#fce4ec,stroke:#c62828
style OLIGO fill:#fce4ec,stroke:#c62828
style PHF fill:#f3e5f5,stroke:#6a1b9a
style NFT fill:#f3e5f5,stroke:#6a1b9a
style SPREAD fill:#fff3e0,stroke:#e65100
style DEATH fill:#ffebee,stroke:#b71c1c
